U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 09732189 | | |
|------------------------|----------------------|---------------------------|--|--|
| Filing Date | | 2000-12-07 | | |
| First Named Inventor | Robert Miller | | | |
| Art Unit | | 2157 | | |
| Examiner Name | Hussein A. El Chanti | | | |
| Attorney Docket Number | | IBM/151 (ROC920000125US1) | | |

| | | | | | U.S.F | PATENTS | | | Remove | |
|---|------------|---|---|-----------------|---------------------------|--|---|----------|---|---|
| Examiner Initial* | Cite No | Patent Number | nt Number Kind Code ¹ Issue Date Name of Patentee or Applica of cited Document | | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | | | |
| | 1 | | | | | | | | | |
| If you wisl | n to a | dd additional U.S. Pate | nt citatio | n inform | ation pl | ease click the | Add button. | | Add | |
| | | | U.S.P | ATENT | APPLIC | CATION PUB | LICATIONS | | Remove | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publica Date | ition | Name of Patentee or Applicant of cited Document | | Releva | ges,Columns,Lines where elevant Passages or Relevant gures Appear | |
| | 1 | | | | | | | | | |
| If you wisl | n to a | dd additional U.S. Publ | ished Ap | plication | citation | n information p | please click the Add | d buttor | Add . | |
| | | | | FOREIG | 3N PAT | ENT DOCUM | ENTS | | Remove | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | | Kind Code ⁴ | Publication Date | Name of Patente Applicant of cited Document | e or | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | т |
| | 1 | | | | | | | | | С |
| If you wisl | n to a | l dd additional Foreign F | atent Do | cument | citation | information pl | lease click the Add | button | Add | _ |
| | | | NON | I-PATE | NT LITE | RATURE DO | CUMENTS | | Remove | |
| Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country volters publisher. | | | | | Тs | | | | | |

| | 1 | *Distributed Parallel Build System for Hierarchically Organized Large Scale Software Systems*, IBM Technical Disclosure Builetin, US, Vol. 39, No. 6, (June 1, 1996), pp. 63-68 | |
|---|------------------|--|---|
| | 2 | Timothy Roy Block, IBM Patent Application filed November 22, 2000, Sensi No 09/716,924, "Apparatus and Method for Communicating Between Computer Systems Using a Sliding Send Window for Ordered Messages in a Clustered Computing Environment." | |
| ı | If you wish to a | dd additional non-patent literature document citation information please click the Add button Add | 1 |

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Examiner Signature

Date Considered

Examiner Signature

Date Considered

¹ See Kind Codes of USPTO Patient Decuments at www.USPTO.GDV or MPEP 901.84. ² Enter office that issued the document, by the law-letter code (WIPO Standard 613.) ² Pea Japanese patient documents, by an indication of the year of the region of the prepare must preced the serial number of the patient code (WIPO Standard 613.4) ² Pea Japanese patient documents, which is the concerns unward with the patient documents, and the patients are standard 613.4 ² peaces the patients of standard 613.4 ² peaces the "Application to place a check mark them?"

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 09732189 | |
|------------------------|------|---------------------------|--|
| Filing Date | | 2000-12-07 | |
| First Named Inventor | Robe | ert Miller | |
| Art Unit | | 2157 | |
| Examiner Name | Huss | ein A. El Chanti | |
| Attorney Docket Number | | IBM/151 (ROC920000125US1) | |

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Scott A Stinebruner

☑ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

38323

| form of the signature. | | | | | | |
|------------------------|------------------------|-------------------|------------|--|--|--|
| Signature | /Scott A. Stinebruner/ | Date (YYYY-MM-DD) | 2006-06-09 | | | |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.231-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.